ストックスクリーナーアプリを入手
25.88
0.73%
-0.19
アフターアワーズ：
25.88
前日終値:
$26.07
開ける：
$26.03
24時間の取引高:
504.42K
Relative Volume:
0.72
時価総額：
$1.11B
収益：
$681.75M
当期純損益:
$70.47M
株価収益率:
17.85
EPS:
1.45
ネットキャッシュフロー:
$173.19M
1週間 パフォーマンス:
-0.54%
1か月 パフォーマンス:
+9.80%
6か月 パフォーマンス:
+8.28%
1年 パフォーマンス:
+37.37%
1日の値動き範囲:
$25.84
$26.36
1週間の範囲:
$25.84
$26.70
52週間の値動き範囲:
$18.17
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
名前
Pacira Biosciences Inc
セクター
電話
650-242-8052
住所
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
PCRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.88 | 1.12B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
125.82 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.11 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Equal Weight |
| 2025-11-17 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-25 | アップグレード | Truist | Hold → Buy |
| 2025-01-30 | アップグレード | Truist | Sell → Hold |
| 2024-08-13 | ダウングレード | Truist | Buy → Sell |
| 2024-08-12 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2024-08-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 再開されました | JP Morgan | Overweight |
| 2023-12-20 | 開始されました | Raymond James | Outperform |
| 2023-08-03 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 再開されました | Wedbush | Outperform |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-01-03 | 再開されました | JP Morgan | Overweight |
| 2021-07-26 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 再開されました | JP Morgan | Neutral |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-02-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 繰り返されました | Needham | Buy |
| 2020-05-27 | 開始されました | Guggenheim | Neutral |
| 2020-04-07 | 開始されました | Northland Capital | Outperform |
| 2020-03-20 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-24 | 開始されました | SunTrust | Buy |
| 2020-01-23 | 開始されました | SunTrust | Buy |
| 2019-11-06 | 開始されました | BTIG Research | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-06 | アップグレード | Mizuho | Underperform → Neutral |
| 2019-05-02 | アップグレード | Stifel | Sell → Hold |
| 2019-02-01 | ダウングレード | Mizuho | Neutral → Underperform |
| 2018-08-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-21 | 繰り返されました | Mizuho | Neutral |
| 2018-02-16 | ダウングレード | Needham | Buy → Hold |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2018-01-04 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-01-03 | 開始されました | Leerink Partners | Mkt Perform |
すべてを表示
Pacira Biosciences Inc (PCRX) 最新ニュース
Big and small, Bay Area companies catch eye of activist shareholders at year's end - The Business Journals
Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale - marketscreener.com
DOMA to nominate three directors to Pacira board, urges company sale By Investing.com - Investing.com Nigeria
DOMA Perpetual Pushes for Strategic Changes at Pacira BioSciences (PCRX) - GuruFocus
Pacira (PCRX) Faces Push for Leadership Change and Strategic Rev - GuruFocus
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - Seeking Alpha
Doma Perpetual Capital Management asserts Pacira BioSciences's board to pursue sale of company - marketscreener.com
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. - PR Newswire
Pacira BioSciences, Inc. $PCRX Shares Sold by Simplify Asset Management Inc. - MarketBeat
Pacer Advisors Inc. Trims Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
75,598 Shares in Pacira BioSciences, Inc. $PCRX Purchased by Exchange Traded Concepts LLC - MarketBeat
Pacira BioSciences (PCRX): How the New PROBE Consortium Partnership Shapes Its Current Valuation - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Neelam Linens and Garments (India) Limited Benefit From Sector TailwindsConsumer Goods Stocks & Free Stock Index Interpretations - bollywoodhelpline.com
OA Gets a Data-Driven PROBE Makeover - Orthopedics This Week
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Investors May Respond To Pacira BioSciences (PCRX) Joining AI-Driven PROBE Osteoarthritis Consortium - Sahm
Pacira BioSciences (PCRX) price target decreased by 18.47% to 30.77 - MSN
Price-Driven Insight from (PCRX) for Rule-Based Strategy - news.stocktradersdaily.com
Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Will Pacira BioSciences Inc. stock maintain momentum in 2025Stop Loss & Weekly Breakout Opportunity Watchlist - Улправда
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care - Ortho Spine News
Will Pacira BioSciences Inc. (82P) stock deliver stable dividendsJuly 2025 Rallies & Risk Controlled Stock Alerts - Улправда
How geopolitical tensions affect Pacira BioSciences Inc. stockWeekly Profit Report & Safe Capital Preservation Plans - DonanımHaber
Why Pacira BioSciences Inc. stock remains a top recommendationJuly 2025 PreEarnings & Short-Term High Return Strategies - DonanımHaber
How rising interest rates impact Pacira BioSciences Inc. stockQuarterly Market Summary & Daily Stock Momentum Reports - DonanımHaber
Pacira BioSciences (PCRX): Assessing Valuation After New PROBE Consortium Osteoarthritis AI Initiative - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
How risky is Pacira BioSciences Inc. stock nowJuly 2025 Highlights & Free Reliable Trade Execution Plans - Улправда
Pacira (PCRX) Joins Global Effort to Enhance Osteoarthritis Rese - GuruFocus
Pacira BioSciences (PCRX): Reassessing Valuation After a 45% Year‑to‑Date Share Price Rally - Yahoo Finance
Pacira BioSciences stock earns technical rating upgrade - MSN
Pacira BioSciences (PCRX) Is Up 7.7% After Positive Spine Pain Pilot Data and New FDA ClearanceHas The Bull Case Changed? - Sahm
Pacira BioSciences Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
EcoR1 Capital LLC Acquires New Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 15,896 Shares - MarketBeat
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) CFO Sells 9,104 Shares of Stock - MarketBeat
Pacira Biosciences CFO cross sells $626k in shares By Investing.com - Investing.com India
Pacira Biosciences CFO cross sells $626k in shares - Investing.com
Pacira BioSciences CFO Shawn Cross Sells 25,000 Shares - TradingView — Track All Markets
CFO Cross Sells 25,000 ($626.8K) Of Pacira BioSciences Inc [PCRX] - TradingView — Track All Markets
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - 富途牛牛
Natixis Buys 151,250 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
(PCRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
CFO Cross Files To Sell 9,104 Of Pacira BioSciences Inc [PCRX] - TradingView — Track All Markets
Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance - Sahm
Pacira BioSciences (NASDAQ:PCRX) Upgraded to Hold at Barclays - MarketBeat
Pacira Biosciences Inc (PCRX) 財務データ
収益
当期純利益
現金流量
EPS
8.30%
0.62%
大文字化:
|
ボリューム (24 時間):